

International Nonproprietary Names for Pharmaceutical Substances (INN)

Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the names given in the list on the following pages are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–65) and Recommended (1–31) International Nonproprietary Names can be found in *Cumulative List No. 8, 1992*. The statements indicating action and use are based largely on information supplied by the manufacturer. This information is merely meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will neither be revised nor included in the Cumulative Lists of INNs.

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Il est notifié que, conformément aux dispositions de l'article 3 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées. L'inclusion d'une dénomination dans les listes de DCI proposées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–65) et recommandées (1–31) dans la *Liste récapitulative No. 8, 1992*. Les mentions indiquant les propriétés et les indications des substances sont fondées sur les renseignements communiqués par le fabricant. Elles ne visent qu'à donner une idée de l'utilisation potentielle des nouvelles substances au moment où elles sont l'objet de propositions de DCI. L'OMS n'est pas en mesure de confirmer ces déclarations ni de faire de commentaires sur l'efficacité du mode d'action ainsi décrit. En raison de leur caractère provisoire, ces informations ne figureront pas dans les listes récapitulatives de DCI.

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

De conformidad con lo que dispone el párrafo 3 del "Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas", se comunica por el presente anuncio que las denominaciones detalladas en las páginas siguientes están sometidas a estudio por la Organización Mundial de La Salud como Denominaciones Comunes Internacionales Propuestas. La inclusión de una denominación en las listas de las DCI Propuestas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–65) y Recomendadas (1–31) se encuentran reunidas en *Cumulative List No. 8, 1992*. Las indicaciones sobre acción y uso que aparecen se basan principalmente en la información facilitada por los fabricantes. Esta información tiene por objeto dar una idea únicamente de las posibilidades de aplicación de las nuevas sustancias a las que se asigna una DCI Propuesta. La OMS no está facultada para respaldar esas indicaciones ni para formular comentarios sobre la eficacia de la acción que se atribuye al producto. Debido a su carácter provisional, esos datos descriptivos no deben incluirse en las listas recapitulativas de DCI.

Proposed International Nonproprietary Names: List 72

Comments on, or formal objections to, the proposed names may be forwarded by any person to the INN Programme of the World Health Organization within four months of the date of their publication in *WHO Drug Information*, i.e., for **List 72 Proposed INN not later than 30 June 1995**.

Dénominations communes internationales proposées: Liste 72

Des observations ou des objections formelles à l'égard des dénominations proposées peuvent être adressées par toute personne au Programme des Dénominations communes internationales de l'Organisation mondiale de la Santé dans un délai de quatre mois à compter de la date de leur publication dans *WHO Drug Information*, c'est à dire pour la **Liste 72 de DCI Proposées le 30 juin 1995 au plus tard**.


Denominaciones Comunes Internacionales Propuestas: Lista 72

Cualquier persona puede dirigir observaciones u objeciones respecto de las denominaciones propuestas, al Programa de Denominaciones Comunes Internacionales de la Organización Mundial de la Salud, en un plazo de cuatro meses, contados desde la fecha de su publicación en *WHO Drug Information*, es decir, para la **Lista 72 de DCI Propuestas el 30 de junio de 1995 a más tardar**.

<i>Proposed INN (Latin, English, French, Spanish)</i>	<i>Chemical name or description: Action and use: Molecular formula Chemical Abstracts Service (CAS) registry number: Graphic formula</i>
<i>DCI Proposée</i>	<i>Nom chimique ou description: Propriétés et indications: Formule brute Numéro dans le registre du CAS: Formule développée</i>
<i>DCI Propuesta</i>	<i>Nombre químico o descripción: Acción y uso: Fórmula empírica Número de registro del CAS: Fórmula desarrollada</i>

acitazanolastum


acitazanolast	3'-(1 <i>H</i> -tetrazol-5-yl)oxanilic acid <i>antiallergic</i>
acitazanolast	acide <i>N</i> -[3-(1 <i>H</i> -tétrazol-5-yl)phényl]oxamique <i>antiallergique</i>
acitazanolast	ácido 3'-(1 <i>H</i> -tetrazol-5-il)oxanílico <i>antialérgico</i>
	C ₉ H ₇ N ₅ O ₃ 114607-46-4



adefovirum

adefovir	[[2-(6-amino-9 <i>H</i> -purin-9-yl)ethoxy]methyl]phosphonic acid <i>antiviral</i>
adéfoviri	acide [[2-(6-amino-9 <i>H</i> -purin-9-yl)éthoxy]méthyl]phosphonique <i>antiviral</i>

adefovir ácido [[2-(6-amino-9H-purin-9-yl)etoxi]metil] fosfónico
antiviral
 C₈H₁₂N₅O₄P 106941-25-7



afelimomabum
 afelimomab

immunoglobulin G 3 (mouse monoclonal LU54107 Fab' fragment γ-chain anti-human tumor necrosis factor α), disulfide with mouse monoclonal LU54107 κ-chain, dimer
immunomodulator

afélimomab

immunoglobuline G 3 (chaîne γ du fragment Fab' de l'anticorps monoclonal de souris LU54107 anti-facteur de nécrose tumorale α humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris LU54107
immunomodulateur

afelimomab

inmunoglobulina G 3 (cadena γ del fragmento Fab' del anticuerpo monoclonal de ratón LU54107 anti-factor de necrosis tumoral α humano), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón LU54107
inmunomodulador

156227-98-4

alniditanum
 alniditan

2-[[[3-[[[(R)-2-chromanylmethyl]amino]propil]amino]-1,4,5,6-tetrahydropyrimidin-2-yl]methyl]-N²-(1,4,5,6-tetrahydropyrimidin-2-yl)propan-1,3-diyl]diamine
antimigraïne, serotonine receptor agonist


alniditan

N-[[[(2R)-3,4-dihydro-2H-chromén-2-yl]méthyl]-N²-(1,4,5,6-tétrahydropyrimidin-2-yl)propan-1,3-diyl]diamine
antimigraïneux, agoniste de la sérotonine

alniditan

2-[[[3-[[[(R)-2-cromanilmetil]amino]propil]amino]-1,4,5,6-tetrahidropirimidina
antimigrañoso, agonista de los receptores de la serotonina

C₁₇H₂₆N₄O 152317-89-0



anakinrum

anakinra

*N*²-L-methionylinterleukin 1 receptor antagonist (human isoform x reduced)
immunomodulator, interleukin-1 receptor antagonist

anakinra

*N*²-L-méthionylantagoniste du récepteur de l'interleukine-1 (isoforme x humaine réduite)
immunomodulateur, antagoniste du récepteur de l'interleukine-1

anakinra

*N*²-L-metionil antagonista del receptor de interleukina 1 (isoforma x reducida, humana)
*inmunomodulador, antagonista del receptor de la interleukina-1*C₇₅₉H₁₁₈₆N₂₀₈O₂₃₂S₁₀ 143090-92-0**anastrozolum**

anastrozole

 $\alpha, \alpha, \alpha', \alpha'$ -tetramethyl-5-(1*H*-1,2,4-triazol-1-ylmethyl)-*m*-benzenediacetonitrile
antineoplastic


anastrozole

2,2'-diméthyl-2,2'-[5-[(1*H*-1,2,4-triazol-1-yl)méthyl]benzène-1,3-diyl]=
dipropanenitrile
antinéoplasique

anastrozol

 $\alpha, \alpha, \alpha', \alpha'$ -tetrametil-5-(1*H*-1,2,4-triazol-1-ilmetil)-*m*-bencendiacetonitrilo
*antineoplásico*C₁₇H₁₉N₅

120511-73-1

**aptiganelum**

aptiganel

1-(*m*-ethylphenyl)-1-methyl-3-(1-naphthyl)guanidine
NMDA receptor antagonist


aptiganel

1-(3-éthylphényl)-1-méthyl-3-(naphtalén-1-yl)guanidine
antagoniste des récepteurs du NMDA

aptiganel


1-(*m*-etilfenil)-1-metil-3-(1-naftil)guanidina
*antagonista de los receptores de NMDA*C₂₀H₂₁N₃

137159-92-3




atexakinum alfa atexakin alfa	1-(1-L-alanyl-L-proline)interleukin 6 (human clone HGF15 protein moiety reduced), cyclic (44→50), (73→83)-bis(disulfide) <i>immunomodulator</i>
atexakine alfa	(44→50), (73→83)-bis(disulfure cyclique) de la [1-(1-L-alanyl-L-proline)]= interleukine 6 (partie protéique réduite de la substance issue du clone humain HGF15) <i>immunomodulateur</i>
atexakina alfa	1-(1-L-alanyl-L-prolina)interleukina 6 (fracción proteica reducida del clon humano HGF15), bis(disulfuro)cíclico (44→50), (73→83) <i>inmunomodulador</i>
	C ₉₁₇ H ₁₄₈₃ N ₂₅₅ O ₂₈₈ S ₉ 143631-61-2

atibepronum atibeprone	7-[(5-isopropyl-1,3,4-thiadiazol-2-yl)methoxy]-3,4-dimethylcoumarin <i>antidepressant</i>
atibéprone	3,4-diméthyl-7-[[5-(1-méthyléthyl)-1,3,4-thiadiazol-2-yl]méthoxy]-2H- chromén-2-one <i>antidépresseur</i>
atibeprona	7-[(5-isopropil-1,3,4-tiadiazol-2-il)metoxi]-3,4-dimetilicumarina <i>antidepresivo</i>
	C ₁₇ H ₁₈ N ₂ O ₃ S 153420-96-3



azimilidum azimilide	1-[[5-(p-chlorophenyl)furfurylidene]amino]-3-[4-(4-methyl-1- piperazinyl)butyl]hydantoin <i>antiarrhythmic</i>
azimilide	1-[[[5-(4-chlorophényl)furan-2-yl]méthylène]amino]-3-[4-(4-méthylpipérazin- 1-yl)butyl]imidazolidine-2,4-dione <i>antiarythmique</i>
azimilida	1-[[5-(p-clorofenil)furfuriliden]amino]-3-[4-(4-metil-1-piperazinil)butil]= hidantoína <i>antiarrítmico</i>
	C ₂₃ H ₂₈ ClN ₅ O ₃ 149908-53-2



basifunginum

basifungin

N-[(2*R*,3*R*)-2-hydroxy-3-methylvaleryl]-*N*-methyl-L-valyl-L-phenylalanyl-*N*-methyl-L-phenylalanyl-L-prolyl-L-alloisoleucyl-*N*-methyl-L-valyl-L-leucyl-3-hydroxy-*N*-methyl-L-valine α_1 -lactone
antifungal

basifungine


α_1 -lactone de la [*N*-[(2*R*,3*R*)-2-hydroxy-3-méthylpentanoyl]-*N*-méthyl-L-valyl]-L-phénylalanyl-(*N*-méthyl-L-phénylalanyl)-L-prolyl-L-allo-isoleucyl-(*N*-méthyl-L-valyl)-L-leucyl-(3-hydroxy-*N*-méthyl-L-valine)
antifongique

basifungina

N-[(2*R*,3*R*)-2-hidroxi-3-metilvaleril]-*N*-metil-L-valil-L-fenilalanil-*N*-metil-L-fenilalanil-L-proil-L-aloisoleucil-*N*-metil-L-valil-L-leucil-3-hidroxi-*N*-metil-L-valina α_1 -lactona
antifúngico

C₆₀H₉₂N₈O₁₁

127785-64-2

**bervastatinum**

bervastatin

ethyl (\pm)-(3*R**,5*S**,6*E*)-7-[4-(*p*-fluorophenyl)spiro[2*H*-1-benzopyran-2,1'-cyclopentan]-3-yl]-3,5-dihydroxy-6-heptenoate
antihyperlipidaemic, HMG-CoA reductase inhibitor

bervastatine


(\pm)-(6*E*)-(3*RS*,5*SR*)-7-[4-(4-fluorophényl)spiro[2*H*-chromène-2,1'-cyclopentane]-3-yl]-3,5-dihydroxyhept-6-énoate d'éthyle
hypolipémiant, inhibiteur de la HMG-CoA réductase

bervastatina

(\pm)-(3*R**,5*S**,6*E*)-7-[4-(*p*-fluorofenil)espiro[2*H*-1-benzopirano-2,1'-ciclopentan]-3-yl]-3,5-dihidroxi-6-heptenoato de etilo
antihiperlipémico, inhibidor de la reductase de la HMG-CoA

C₂₈H₃₁FO₅

132017-01-7



and enantiomer
et énantiomère
y enantiómero

betasizofiranum

betasizofiran

scleroglucan or poly[→3(O-β-D-glucopyranosyl-(1→3)-O-[β-D-glucopyranosyl-(1→6)]-O-β-D-glucopyranosyl-(1→3)-O-β-D-glucopyranosyl-(1→)] produced by *Sclerotium rolfsii*; relative molecular mass is about 5.10^6
laxative

bétasizofiran


scéléroglycane ou poly[→3(O-β-D-glucopyranosyl-(1→3)-O-[β-D-glucopyranosyl-(1→6)]-O-β-D-glucopyranosyl-(1→3)-O-β-D-glucopyranosyl-(1→)] produit par *Sclerotium rolfsii*; la masse moléculaire relative est voisine de 5.10^6
laxatif

betasizofiran

escleroglucano ó poli[→3(O-β-D-glucopiranosil-(1→3)-O-[β-D-glucopiranosil-(1→6)]-O-β-D-glucopiranosil-(1→3)-O-β-D-glucopiranosil-(1→)] producido por *Sclerotium rolfsii*; la masa molecular relativa es aproximadamente de 5.10^6
laxante

 $(C_{24}H_{40}O_{20})_n$

39464-87-4

**bivalirudinum**

bivalirudin

D-phenylalanyl-L-prolyl-L-arginyl-L-prolyl-glycyl-glycyl-glycyl-glycyl-L-asparaginyl-glycyl-L-α-aspartyl-L-phenylalanyl-L-α-glutamyl-L-α-glutamyl-L-isoleucyl-L-prolyl-L-α-glutamyl-L-α-glutamyl-L-tyrosyl-L-leucine
anticoagulant

bivalirudine

D-phénylalanil-L-proliil-L-arginil-L-proliil-glycyl-glycyl-glycyl-glycyl-L-asparaginil-glycyl-L-α-aspartil-L-phénylalanil-L-α-glutamyl-L-α-glutamyl-L-isoleucil-L-proliil-L-α-glutamyl-L-α-glutamyl-L-tyrosil-L-leucine
anticoagulant

bivalirudina

D-fenilalanil-L-proliil-L-arginil-L-proliilglicilglicilglicilglicil-L-asparraginilglicil-L-α-aspartil-L-fenilalanil-L-α-glutamil-L-α-glutamil-L-isoleucil-L-proliil-L-α-glutamil-L-α-glutamil-L-tirosil-L-leucina
anticoagulante

 $C_{98}H_{138}N_{24}O_{33}$

128270-60-0

H-D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-

Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH

capecitabinum

capecitabine

1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
antineoplástica

capécitabine


acide [1-(5-désoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamique
antineoplasique

capecitabina

ácido 1-(5-desoxi-β-D-ribofuranosil)-5-fluoro-1,2-dihidro-2-oxo-4-pirimidincarbámico
antineoplásico

C₁₀H₁₂FN₃O₆

158798-73-3

**cartasteinum**

cartasteine

(S)-3-[N-[(R)-2-mercaptopropionyl]glycyl]-4-thiazolidinecarboxylic acid
mucolytic

cartastéine


acide (4S)-3-[2-[[[(2R)-2-mercaptoopropanoyl]amino]acétyl]thiazolidine-4-carboxylique
mucolytique

cartasteina

ácido (S)-3-[N-[(R)-2-mercaptopropionil]glicil]-4-tiazolidinecarbóxico
mucolítico

C₉H₁₄N₂O₄S₂

149079-51-6

**cidofovirum**


cidofovir

[[[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl]=phosphonic acid
antiviral

cidofovir

acide [[[1(S)-2-(4-amino-2-oxopyrimidin-1(2H)-yl)-1-(hydroxyméthyl)éthoxy]=méthyl]phosphonique
antiviral

cidofovir ácido [[[*S*]-2-(4-amino-2-oxo-1(2*H*)-pirimidinil)-1-(hidroximetil)etoxi]metil]=
fosfónico
antiviral
C₈H₁₄N₃O₆P 113852-37-2


**cromoglicas lisetilum**

cromoglicate lisetil diethyl 5,5'-[(2-hydroxytrimethylene)dioxy]bis[4-oxo-4*H*-1-benzopyran-
2-carboxylate], ester with L-lysine
antiallergic, antiasthmatic

cromoglicate lisétíl (+)-5,5'-[[2-[[[(2*S*)-2,6-diaminohexanoyl]oxy]propane-1,3-diyl]dioxo]bis(4-oxo-
4*H*-chromène-2-carboxylate d'éthyle)
antiallergique, antiasthmatique

cromoglicato lisetil 5,5'-[(2-hidroxitrimetileno)dioxi]bis[4-oxo-4*H*-1-benzopirano-
2-carboxilato] de dietilo, éster con L-lisina
antialérgico, antiasmático

C₃₃H₃₆N₂O₁₂ 110816-79-0

**ebalzotanum**


ebalzotan (*R*)-*N*-isopropyl-3-(isopropylpropilamino)-5-chromancarboxamide
serotonin receptor agonist

ébalzotan (3*R*)-*N*-(1-méthyléthyl)-3-[(1-méthyléthyl)propilamino]-3,4-dihydro-
2*H*-chromène-5-carboxamide
agoniste de la sérotonine

ebalzotan (*R*)-*N*-isopropil-3-(isopropilpropilamino)-5-cromancarboxamida
agonista de los receptores de la serotonina

C₁₉H₃₀N₂O₂

149494-37-1

**elisartanum**

elisartan

(±)-1-hydroxyethyl 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-yl)phenyl]benzyl]=
imidazole-5-carboxylate, ethyl carbonate (ester)
angiotensin II receptor antagonist

élisartan


2-butyl-4-chloro-1-[4-[2-(1H-tétrazol-5-yl)phényl]benzyl]-1H-imidazol-
5-carboxylate de (RS)-1-[(éthoxycarbonyl)oxy]éthyle
antagoniste du récepteur de l'angiotensine II

elisartan

(±)-2-butil-4-cloro-1-[p-(o-1H-tetrazol-5-ilfenil)benzil]imidazol-
5-carboxilato,etil carbonato de 1-hidroxietilo (éster)
antagonista del receptor de angiotensina II

C₂₇H₂₉ClN₆O₅

158682-68-9



and enantiomer
et énantiomère
y enantiomero

epoetinum epsilon

epoetin epsilon

1-165-erythropoietin (human clone λHEPOFL13 protein moiety), glycoform ε
antianaemic

époétine epsilon

1-165-érythropoïétine (partie protéique du clone humain λHEPOFL13), forme
glycosylée ε
antianémique

epoetina epsilon

1-165-eritropoietina (fracción proteica del clon humano λHEPOFL13), forma
glicosilada ε
antianémico

C₈₀₉H₁₃₀₁N₂₂₉O₂₄₀S₅ 154725-65-2


(for non-glycosylated protein)

(pour la protéine non glycosylée)


(fracción proteica no glicosilada)

eptacogum alfa (activatum)	
eptacog alfa (activated)	blood-coagulation factor VII (human clone λHVII2463 protein moiety) <i>blood-coagulation factor</i>
eptacog alfa (activé)	facteur VII de coagulation sanguine (partie protéique de la substance issue du clone humain λHVII2463) <i>facteur de coagulation sanguine</i>
eptacog alfa (activado)	factor de coagulación VII (fracción proteica del clon humano λHVII2463) <i>factor de coagulación sanguínea</i>
	C ₂₆₂₁ H ₄₀₅₆ N ₇₂₈ O ₈₁₂ S ₃₆ 102786-52-7

ersentilidum	
ersentilide	4'-[(2 <i>S</i>)-2-hydroxy-3-[[2-(<i>p</i> -imidazol-1-ylphenoxy)ethyl]amino]propoxy]=methanesulfonanilide <i>antiarrhythmic</i>
ersentilide	<i>N</i> -[4-[[[(<i>S</i>)-2-hydroxy-3-[[2-[4-(1 <i>H</i> -imidazol-1-yl)phénoxy]éthyl]amino]propyl]=oxy]phényl]méthanesulfonamide <i>antiarythmique</i>
ersentilida	4'-[(2 <i>S</i>)-2-hidroxi-3-[[2-(<i>p</i> -imidazol-1-ilfenoxi)etil]amino]propoxi]=metansulfonanilida <i>antiarrítmico</i>
	C ₂₁ H ₂₆ N ₄ O ₅ S 125279-79-0



examorelinum	
examorelin	L-histidyl-2-methyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysineamide <i>growth hormone release stimulating peptide</i>
examoréline	L-histidyl-(2-méthyl-D-tryptophyl)-L-alanyl-L-tryptophyl-D-phénylalanyl-L-lysineamide <i>peptide stimulant la libération de l'hormone de croissance</i>
examorelina	L-histidil-2-metil-D-triptofil-L-alanil-L-triptofil-D-fenilalanil-L-lisinamida <i>peptido estimulante de la liberación de la hormona del crecimiento</i>
	C ₄₇ H ₅₈ N ₁₂ O ₆ 140703-51-1



fampridinum

fampridine

4-aminopyridine
potassium channel blocker


fampridine

pyridin-4-ylamine
antagoniste potassique

fampridina

4-aminopiridina
*antagonista del potasio*C₅H₆N₂

504-24-5

**fenleutonum**

fenleuton

(±)-1-[3-[*m*-(*p*-fluorophenoxy)phenyl]-1-methyl-2-propynyl]-1-hydroxyurea
leukotriene synthesis inhibitor


fenleuton

(±)-1-[(1*RS*)-3-[3-(4-fluorophénoxy)phényl]-1-méthylprop-2-ynyl]-1-hydroxyurée
inhibiteur de la synthèse des leucotriènes

fenleuton

(±)-1-[3-[*m*-(*p*-fluorofenoxi)fenil]-1-metil-2-propinil]-1-hidroxiurea
*inhibidor de la síntesis de leucotrienos*C₁₇H₁₅FN₂O₃

141579-54-6

and enantiomer
et énantiomère
y enantiómero**fodipirum**

fodipir

N,N'-ethylenebis[*N*-[[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridyl]=methyl]glycine] 5,5'-bis(dihydrogenphosphate)
diagnostic agent

fodipir


N,N'-éthane-1,2-diylbis[*N*-[[3-hydroxy-2-méthyl-5-[(phosphonoxy)méthyl]=pyridin-4-yl]méthyl]glycine]
produit à usage diagnostique

fodipir

N,N'-etilenbis[*N*-[[3-hidroxi-5-(hidroximetil)-2-metil-4-piridil]=metil]glicina] 5,5'-bis(dihidrógenofosfato)
agente de diagnóstico

C₂₂H₃₂N₄O₁₄P₂

118248-91-2

**fradafibanum**

fradafiban

(3*S*,5*S*)-5-[[[4'-amidino-4-biphenyl]oxy]methyl]-2-oxo-3-pyrrolidineacetic acid*fibrinogen receptor antagonist*


fradafiban

acide 2-[[[3*S*,5*S*)-5-[[[4'-amidinobiphényl-4-yl]oxy]méthyl]-2-oxopyrrolidin-3-yl]acétique*antagoniste du récepteur du fibrinogène*

fradafiban

ácido (3*S*,5*S*)-5-[[[4'-amidino-4-bifenilil]oxi]metil]-2-oxo-3-pirrolidinacético*antagonista del receptor del fibrinógeno*C₂₀H₂₁N₃O₄

148396-36-5

**galdansetronum**

galdansetron

(+)-(3*R*)-2,3-dihydro-9-methyl-3-[(5-methylimidazol-4-yl)methyl]carbazol-4(1*H*)-one*serotonin receptor antagonist*


galdansétron

(+)-(3*R*)-9-méthyl-3-[(5-méthyl-1*H*-imidazol-4-yl)méthyl]-1,2,3,9-tétrahydro-4*H*-carbazol-4-one*antagoniste de la sérotonine*

galdansetron

(+)-(3*R*)-2,3-dihidro-9-metil-3-[(5-metilimidazol-4-il)metil]carbazol-4(1*H*)-ona*antagonista de los receptores de la serotonina*C₁₈H₁₉N₃O

116684-92-5




goralatum

goralatumide 1-[N²-[N-(N-acetyl-L-seryl)-L- α -aspartyl]-L-lysyl]-L-proline
immunomodulator

goralatumide (N-acétyl-L-séryl)-L- α -aspartyl-L-lysyl-L-proline
immunomodulateur

goralatumida 1-[N²-[N-(N-acetil-L-seril)-L- α -aspartil]-L-lisil]-L-prolina
immunomodulador

C₂₀H₃₃N₅O₉ 120081-14-3

**imiglucerasum**

imiglucerase 495-L-histidineglucosylceramidase (human placenta isoenzyme protein moiety)
enzyme

imiglucérase [495-L-histidine]glucosylcér amidase (partie protéique d'isoenzyme de placenta humain)
enzyme

imiglucerasa 495-L-histidinagluco silceramidasa (isoenzima de placenta humana, fracción proteica)
enzima

C₂₅₃₂H₃₈₄₃N₆₇₁O₇₁₁S₁₆ 154248-97-2

inogatranum


inogatran N-[(1*R*)-2-cyclohexyl-1-[[[(2*S*)-2-[(3-guanidinopropyl)carbamoil]piperidino]=carbonyl]ethyl]glycine
thrombin inhibitor

inogatran acide 2-[[[(1*R*)-1-(cyclohexylméthyl)-2-[(2*S*)-2-[[[(3-guanidinopropyl)amino]=carbonyl]pipéridin-1-yl]-2-oxoéthyl]amino]acétique
inhibiteur de la thrombine

inogatran N-[(1*R*)-2-ciclohexil-1-[[[(2*S*)-2-[(3-guanidinopropil)carbamoil]piperidino]=carbonil]etil]glicina
inhibidor de la trombina

C₂₁H₃₈N₆O₄

155415-08-0

**insulinum lisprum**

insulin lispro

28^B-L-lysine-29^B-L-prolineinsulin (human)
antidiabétique

insuline lispro

[28^B-L-lysine-29^B-L-proline]insuline humaine
antidiabétique

insulina lispro

28^B-L-lisina-29^B-L-prolinainsulina (humana)
*antidiabético*C₂₅₇H₃₈₃N₆₅O₇₇S₆

133107-64-9

lamifibanum

lamifiban

[[1-[N-(p-amidinobenzoyl)-L-tyrosyl]-4-piperidyl]oxy]acetic acid
fibrinogen receptor antagonist


lamifiban

acide 2-[[1-[(2S)-2-[(4-amidinobenzoyl)amino]-3-(4-hydroxyphényl)]propanoyl]pipéridin-4-yl]oxy]acétique
antagoniste du récepteur du fibrinogène

lamifiban

ácido[[1-[N-(p-amidinobenzoil)-L-tirosil]-4-piperidil]oxi] acético
*antagonista del receptor del fibrinógeno*C₂₄H₂₈N₄O₆

144412-49-7



lanperisonum

lanperisone

(-)-(R)-2-methyl-3-(1-pyrrolidinyl)-4'-(trifluoromethyl)propiofenone
central muscle relaxant

lanpérisonne


(-)-(2R)-2-méthyl-3-(pyrrolidin-1-yl)-1-[4-(trifluorométhyl)phényl]propan-1-one
myorelaxant central

lanperisona

(-)-(R)-2-metil-3-(1-pirrolidinil)-4'-(trifluorometil)propiofenona
miorelajante central

C₁₅H₁₈F₃NO

116287-14-0

**lanprostonum**

lanprostion


(Z)-7-[(1R,2R,3R,5S)-2-[(E)-2-[2-[(m-chlorophenoxy)methyl]-1,3-dioxolan-2-yl]vinyl]-3,5-dihydroxycyclopentyl]-5-heptenoic acid
luteotropic agent (vet.)

lanprostione

acide (5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-2-[2-[(3-chlorophénoxy)méthyl]-1,3-dioxolan-2-yl]éthényl]-3,5-dihydroxycyclopentyl]hept-5-énoïque
agent lutéotrope (vét.)

lanprostion

ácido (Z)-7-[(1R,2R,3R,5S)-2-[(1E)-2-[2-[(m-clorofenoxi)metil]-1,3-dioxolan-2-il]vinil]-3,5-dihidroxíciclopentil]-5-heptenoico
luteotrópico (vet.)

C₂₄H₃₁ClO₇**lenerceptum**

lenercept

1-182-tumor necrosis factor receptor (human reduced), (182→104')-protein with 104-330-immunoglobulin G 1 (human clone pTJ5 Cγ 1 reduced)
tumor necrosis factor antagonist

lénercept

1-182-récepteur du facteur de nécrose tumorale (humain réduit), (182→104')-protéine avec la 104-330-immunoglobuline G 1 (clone humain pTJ5 Cγ 1 réduit)
antagoniste du facteur de nécrose tumorale

lenercept

1-182-receptor del factor de necrosis tumoral (humano reducido), (182→104')-proteina con la 104-330-inmunoglobulina G 1 (clon humano pTJ5 Cγ 1 reducido)
antagonista del factor de necrosis tumoral

C₁₉₉₃H₃₁₁₂N₅₆₂O₆₂₄S₃₄ 156679-34-4

levosemotiadilum

levosemotiadil

(-)-(S)-2-[5-methoxy-2-[3-[methyl[2-[3,4-(methylenedioxy)phenoxy]ethyl]=amino]propoxy]phenyl]-4-methyl-2H-1,4-benzothiazin-3(4H)-one
antiarrhythmic

lévosémotiadiil


(-)-(2S)-2-[2-[[3-[[2-(1,3-benzodioxol-5-yloxy)éthyl]méthylamino]propyl]oxy]-5-méthoxyphényl]-4-méthyl-2H-1,4-benzothiazin-3(4H)-one
antiarythmique

levosemotiadil

(-)-(S)-2-[5-metoxi-2-[3-[metil[2-[3,4-(metilendioxi)fenoksi]etil]=amino]propoxi]fenil]-4-metil-2H-1,4-benzotiazin-3(4H)-ona
antiarrítmico

C₂₉H₃₂N₂O₆S

116476-16-5

**lirequinilum**

lirequinil

(3S)-1-[(10-chloro-6,7-dihydro-4-oxo-3-phenyl-4H-benzo[a]quinolizin-1-yl)=carbonyl]-3-ethoxypyrrolidine
hypnotic

liréquinil


(3S)-1-[(10-chloro-4-oxo-3-phényl-6,7-dihydro-4H-benzo[a]quinolizin-1-yl)=carbonyl]-3-éthoxypyrrolidine
hypnotique

lirequinilo

(3S)-1-[(10-cloro-6,7-dihidro-4-oxo-3-fenil-4H-benzo[a]quinolizin-1-il)=carbonil]-3-etoxipirrolidina
hipnótico

C₂₆H₂₅ClN₂O₃

143943-73-1



lisofyllinum

lisofylline

1-[(*R*)-5-hydroxyhexyl]theobromine
non-steroidal anti-inflammatory


lisofylline

1-[(5*R*)-5-hydroxyhexyl]-3,7-diméthyl-3,7-dihydro-1*H*-purin-2,6-dione
anti-inflammatoire non-stéroïdien

lisofilina

1-[(*R*)-5-hidroxihexil]teobromina
*antiinflamatorio no esteroideo*C₁₃H₂₀N₄O₃

100324-81-0

**lobucavirum**

lobucavir

9-[(1*R*,2*R*,3*S*)-2,3-bis(hydroxyméthyl)cyclobutyl]guanine
antiviral


lobucavir

2-amino-9-[(1*R*,2*R*,3*S*)-2,3-bis(hydroxyméthyl)cyclobutyl]-1,9-dihydro-6*H*-
purin-6-one
antiviral

lobucavir

9-[(1*R*,2*R*,3*S*)-2,3-bis(hidroxi metil) ciclobutil]guanina
*antiviral*C₁₁H₁₅N₅O₃

127759-89-1

**mangafodipirum**

mangafodipir


hexahydrogen (OC-6-13)-[[*N,N'*-ethylenebis[*N*-[[3-hydroxy-
5-(hydroxyméthyl)-2-méthyl-4-pyridyl]méthyl]glycine] 5,5'-bis(phosphato)](8-)]
manganate(6-)
diagnostic agent

mangafodipir

(OC-6-13)-hexahydrogénéo[[*N,N'*-ethane-1,2-diylbis[*N*-[[3-hydroxy-2-méthyl-
5-[(phosphonoxy)méthyl]pyridin-4-yl]méthyl]glycinato]](8-)]manganate(6-)]
produit à usage diagnostique

mangafodipir

hexahidrógeno (OC-6-13)-[[*N,N'*-etilenbis[*N*-[[3-hidroxi-5-(hidroximetil)-
2-metil-4-piridil]metil]glicina] 5,5'-bis(fosfato)](8-)]manganato(6-)]
agente de diagnóstico

C₂₂H₃₀MnN₄O₁₄P₂ 155319-91-8

mapinastinum
mapinastine


1-(2-ethoxyethyl)-2-[[4-(4-pyrazol-1-ylbutyl)-1-piperazinyl]methyl]=
benzimidazole
antihistaminic, antiallergic

mapinastine

1-(2-éthoxyéthyl)-2-[[4-[4-(1*H*-pyrazol-1-yl)butyl]pipérazin-1-yl]méthyl]-1*H*-
benzimidazole
antihistaminique, antiallergique

mapinastina

1-(2-etoxietil)-2-[[4-(4-pirazol-1-ilbutil)-1-piperazinil]metil]bencimidazol
antihistamínico, antialérgico

C₂₃H₃₄N₆O 140945-32-0

marsidominum
marsidomine


3-(*cis*-2,6-dimethylpiperidino)sydnone imine
antianginal

marsidomine

3-(*cis*-2,6-diméthylpipéridin-1-yl)sydnone imine
antiangoreux

marsidomina

3-(*cis*-2,6-dimetilpiperidino)sidnona imina
antianginoso

C₉H₁₆N₄O 137500-42-6

mazapertinum

mazapertine

1-[α -[4-(*o*-isopropoxyphenyl)-1-piperazinyl]-*m*-toluoyl]piperidine
antipsychotic, dopamin D₂ receptor antagonist


mazapertine

1-[3-[4-[2-(1-méthyléthoxy)phényl]pipérazin-1-yl]méthyl]benzoyl]pipéridine
psychotrope, antagoniste du récepteur D₂ de la dopamine

mazapertina

1-[α -[4-(*o*-isopropoxifenil)-1-piperazinil]-*m*-toluoil]piperidina
*antipsicótico, antagonista del receptor D₂ de la dopamina*C₂₆H₃₅N₃O₂

134208-17-6

**mibefradilum**

mibefradil

(1*S*,2*S*)-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate
calcium channel blocker


mibéfradil

2-méthoxyacétate de (1*S*,2*S*)-2-[2-[[3-(1*H*-benzimidazol-2-yl)propyl]méthylamino]éthyl]-6-fluoro-1-(1-méthyléthyl)-1,2,3,4-tétrahydronaphtalén-2-yle
antagoniste calcique

mibefradil

(1*S*,2*S*)-2-[2-[[3-(2-benzimidazolil)propil]metilamino]etil]-6-fluoro-1,2,3,4-tetrahidro-1-isopropil-2-naftil metoxiacetato
*antagonista del calcio*C₂₉H₃₈FN₃O₃

116644-53-2

**mirisetrinum**

mirisetrone

1-cyclohexyl-1,4-dihydro-4-oxo-*N*-1 α *H*,5 α *H*-tropan-3 α -yl-3-quinoline=carboxamide
anxiolytic

mirisétron


1-cyclohexyl-*N*-[(1*R*,3*r*,5*S*)-8-méthyl-8-azabicyclo[3.2.1]oct-3-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxamide
anxiolytique

mirisetrone

1-ciclohexil-1,4-dihidro-4-oxo-*N*-1 α *H*,5 α *H*-tropan-3 α -il-3-quinolina=carboxamida
ansiolítico

C₂₄H₃₁N₃O₂

135905-89-4

**mobenakinum**

mobenakin

71-L-serineinterleukin 1 β (human clone pIL-1-14 reduced)
immunomodulator

mobénakine

[71-L-sérine]interleukine 1 β (clone humain pIL-1-14, réduite)
immunomodulateur

mobenakina

71-L-serinainterleuquina 1 β (clon humano pIL-1-14 reducido)
*inmunomodulador*C₇₇₃H₁₂₁₉N₂₀₁O₂₃₈S₇ 124146-64-1**moroctocogum alfa**

moroctocog alfa

(1-742)-(1637-1648)-blood-coagulation factor VIII (human reduced) complex
with 1649-2332-blood-coagulation factor VIII (human reduced)
blood-coagulation factor

moroctocog alfa

complexe du (1-742)-(1637-1648)-facteur VIII de coagulation sanguine
(humain réduit) avec le 1649-2332-facteur VIII de coagulation sanguine
(humain réduit)
facteur de coagulation sanguine

moroctocog alfa

(1-742)-(1637-1648)-factor de coagulación VIII (humano reducido) complejo
con 1649-2332-factor de coagulación VIII (humano reducido)
*factor de coagulación sanguínea*C₃₉₅₃H₆₀₂₀N₁₀₄₀O₁₁₅₈S₂₉C₃₅₅₃H₅₄₁₂N₉₅₆O₁₀₂₈S₃₃**muplestimum**

muplestim

interleukin 3 (human protein moiety reduced)
immunomodulator

muplestim

interleukine 3 (partie protéique humaine réduite)
immunomodulateur

muplestim

interleukina 3 (fracción proteica reducida humana)
*inmunomodulador*C₆₇₀H₁₀₇₆N₁₈₆O₁₉₉S₅ 113315-09-6

napsagatranum

napsagatran

N-[*N*⁴-[[[(3*S*)-1-amidino-3-piperidyl]methyl]-*N*²-(2-naphthylsulfonyl)-*L*-asparaginy]]-*N*-cyclopropylglycine
thrombin inhibitor

napsagatran


acide 2-[[[(2*S*)-4-[[[(3*S*)-1-amidinopipéridin-3-yl]méthyl]amino]-2-[[naph= talén-2-yl)sulfonyl]amino]-4-oxobutanoyl](cyclopropyl)amino]acétique
inhibiteur de la thrombine

napsagatran

N-[*N*⁴-[[[(3*S*)-1-amidino-3-piperidil]metil]-*N*²-(2-naftilsulfonyl)-*L*-asparragini]]-*N*-ciclopropilglicina
inhibidor de la trombina

C₂₆H₃₄N₆O₆S

154397-77-0

**netivudinum**

netivudine

1-β-D-arabinofuranosyl-5-(1-propynyl)uracil
antiviral

nétivudine


1-(β-D-arabinofuranosyl)-5-(prop-1-ynyl)pyrimidine-2,4(1*H*,3*H*)-dione
antiviral

netivudina

1-β-D-arabinofuranosil-5-(1-propinil)uracilo
antiviral

C₁₂H₁₄N₂O₆

84558-93-0

**nicanartinum**


nicanartine

2,6-di-*tert*-butyl-4-[3-(3-pyridylmethoxy)propyl]phenol
antihyperlipidaemic

nicanartine

2,6-bis(1,1-diméthyléthyl)-4-[3-[(pyridin-3-yl)méthoxy]propyl]phénol
hypolipémiant


nicanartina
 2,6-di-*tert*-butil-4-[3-(3-piridilmetoksi)propil]fenol
antihiperlipémico
 $C_{23}H_{33}NO_2$ 150443-71-3



nicotredolum
 nicotredole
N-(2-indol-3-ylethyl)nicotinamide
non-steroidal anti-inflammatory (vet.)

nicotredole
N-[2-(1*H*-indol-3-yl)éthyl]pyridine-3-carboxamide
anti-inflammatoire non-stéroïdien (vét.)


nicotredol
N-(2-indol-3-iletil)nicotinamida
antiinflamatorio no esteroideo (vet.)
 $C_{16}H_{15}N_3O$ 29876-14-0



ocinaplونum
 ocinaplون
 2-pyridyl 7-(4-pyridyl)pyrazolo[1,5-*a*]pyrimidin-3-yl ketone
anxiolytic


ocinaplone
 (pyridin-2-yl)[7-(4-pyridin-4-yl)pyrazolo[1,5-*a*]pyrimidin-3-yl]méthanone
anxiolytique

ocinaplون
 2-piridil 7-(4-piridil)pirazolo[1,5-*a*]pirimidin-3-il cetona
ansiolítico
 $C_{17}H_{11}N_5O$ 96604-21-6




olopatadinum
 olopatadine
 11-[(*Z*)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[*b,e*]oxepin-2-acetic acid
antiallergic

olopatadine	acide 2-[11-[(1 <i>Z</i>)-3-(diméthylamino)propylidène]-6,11-dihydrodibenzo= [<i>b</i> , <i>e</i>]oxépin-2-yl]acétique <i>antiallergique</i>
olopatadina	ácido 11-[(<i>Z</i>)-3-(dimetilamino)propiliden]-6,11-dihidrodibenz[<i>b</i> , <i>e</i>]oxepin-2- acético <i>antialérgico</i>
	C ₂₁ H ₂₃ NO ₃ 113806-05-6



ontazolastum	
ontazolast	2-[[(<i>S</i>)-2-cyclohexyl-1-(2-pyridyl)éthyl]amino]-5-méthylbenzoxazole <i>antiasthmatic</i>
ontazolast	[[1(<i>S</i>)-2-cyclohexyl-1-(pyridin-2-yl)éthyl](5-méthylbenzoxazol-2-yl)amine <i>antiasthmatique</i>
ontazolast	2-[[(<i>S</i>)-2-ciclohexil-1-(2-piridil)etil]amino]-5-metilbenzoxazol <i>antiasmático</i>
	C ₂₁ H ₂₅ N ₃ O 147432-77-7




orientiparcinum	
orientiparcin	a mixture of orienticine A and orienticine D, orienticine A (major component): (-)-(3 <i>S</i> ,6 <i>R</i> ,7 <i>R</i> ,22 <i>R</i> ,23 <i>S</i> ,26 <i>S</i> ,36 <i>R</i> ,38 <i>a</i> <i>F</i>)-22-[[3-amino-2,3,6-trideoxy-3- <i>C</i> - methyl- α - <i>L</i> -arabino-hexopyranosyl]oxy]-44-[[2- <i>O</i> -(3-amino-2,3,6-trideoxy-3- <i>C</i> -methyl- α - <i>L</i> -arabino-hexopyranosyl)- β - <i>D</i> -glucopyranosyl]oxy]-3- (carbamoylmethyl)-19-chloro-2,3,4,5,6,7,23,24,25,26,36,37,38,38 <i>a</i> - tetradecahydro-7,28,30,32-tetrahydroxy-6-[(2 <i>R</i>)-4-methyl-2- (methylamino)valeramido-2,5,24,38,39-pentaoso-22 <i>H</i> -8,11:18,21-dietheno- 23,36-(iminomethano)-13,16:31,35-dimetheno-1 <i>H</i> ,16 <i>H</i> - [1,6,9]oxadiazacyclohexadecino[4,5- <i>m</i>][10,2,16]benzoxadiazac= cyclotetracosine-26-carboxylic acid

	<p>orienticine D (minor component) : (-)-(3<i>S</i>,6<i>R</i>,7<i>R</i>,22<i>R</i>,23<i>S</i>,26<i>S</i>,36<i>R</i>,38<i>aR</i>)-22-[(3-amino-2,3,6-trideoxy-3-<i>C</i>-methyl-α-<i>L</i>-<i>arabino</i>-hexopyranosyl)oxy]-44-[[2-<i>O</i>-(3-amino-2,3,6-trideoxy-3-<i>C</i>-methyl-α-<i>L</i>-<i>arabino</i>-hexopyranosyl)-β-<i>D</i>-glucopyranosyl]oxy]-3-(carbamoylmethyl)-19-chloro-6-[(2<i>R</i>)-2-(dimethylamino)-4-methylvaleramido]-2,3,4,5,6,7,23,24,25,26,36,37,38,38<i>a</i>-tetradecahydro-7,28,30,32-tetrahydroxy-2,5,24,38,39-pentaoxo-22<i>H</i>-8,11:18,21-dietheno-23,36-(iminomethano)-13,16:31,35-dimetheno-1<i>H</i>,16<i>H</i>-[1,6,9]oxadiazacyclohexadecino[4,5-<i>m</i>][10,2,16]benzoxadiazacyclotetracosine-26-carboxylic acid <i>antibacterial (vet.)</i></p>
orientiparcine	<p>mélange d'orienticine A et d'orienticine D, orienticine A (constituant principal): acide (3<i>S</i>,6<i>R</i>,7<i>R</i>,22<i>R</i>,23<i>S</i>,26<i>S</i>,36<i>R</i>,38<i>aR</i>)-22-[(3-amino-3-<i>C</i>-méthyl-2,3,6-tridésoxy-α-<i>L</i>-<i>arabino</i>-hexopyranosyl)oxy]-44-[[2-<i>O</i>-(3-amino-3-<i>C</i>-méthyl-2,3,6-tridésoxy-α-<i>L</i>-<i>arabino</i>-hexopyranosyl)-β-<i>D</i>-glucopyranosyl]oxy]-3-(carbamoylméthyl)-19-chloro-7,28,30,32-tétrahydroxy-6-[[<i>R</i>]-4-méthyl-2-(méthylamino)pentanoyl]amino]-2,5,24,38,39-pentaoxo-2,3,4,5,6,7,23,24,25,26,36,37,38,38<i>a</i>-tétradécahydro-8,11:18,21-diéthéno-23,36-(iminométhano)-22<i>H</i>-13,16:31,35-diméthéno-1<i>H</i>,13<i>H</i>-[1,6,9]oxadiazacyclohexadécino[4,5-<i>m</i>][10,2,16]benzoxadiazacyclotétracosène-26-carboxylique orienticine D (constituant secondaire): acide (3<i>S</i>,6<i>R</i>,7<i>R</i>,22<i>R</i>,23<i>S</i>,26<i>S</i>,36<i>R</i>,38<i>aR</i>)-22-[(3-amino-3-<i>C</i>-méthyl-2,3,6-tridésoxy-α-<i>L</i>-<i>arabino</i>-hexopyranosyl)oxy]-44-[[2-<i>O</i>-(3-amino-3-<i>C</i>-méthyl-2,3,6-tridésoxy-α-<i>L</i>-<i>arabino</i>-hexopyranosyl)-β-<i>D</i>-glucopyranosyl]oxy]-3-(carbamoylméthyl)-19-chloro-7,28,30,32-tétrahydroxy-6-[[<i>R</i>]-2-(diméthylamino)-4-méthylpentanoyl]amino]-2,5,24,38,39-pentaoxo-2,3,4,5,6,7,23,24,25,26,36,37,38,38<i>a</i>-tétradécahydro-8,11:18,21-diéthéno-23,36-(iminométhano)-22<i>H</i>-13,16:31,35-diméthéno-1<i>H</i>,13<i>H</i>-[1,6,9]oxadiazacyclohexadécino[4,5-<i>m</i>][10,2,16]benzoxadiazacyclotétracosène-26-carboxylique <i>antibactérien (vét.)</i></p>
orientiparcina	<p>mezcla de orienticina A y de orienticina D, orienticina A (constituyente principal): ácido (3<i>S</i>,6<i>R</i>,7<i>R</i>,22<i>R</i>,23<i>S</i>,26<i>S</i>,36<i>R</i>,38<i>aR</i>)-22-[(3-amino-3-<i>C</i>-metil-2,3,6-tridesoxi-α-<i>L</i>-<i>arabino</i>-hexopiranosil)oxi]-44-[[2-<i>O</i>-(3-amino-3-<i>C</i>-metil-2,3,6-tridesoxi-α-<i>L</i>-<i>arabino</i>-hexopiranosil)-β-<i>D</i>-glucopiranosil]oxi]-3-(carbamoilmetil)-19-cloro-7,28,30,32-tetrahidroxi-6-[[<i>R</i>]-4-metil-2-(metilamino)pentanoil]amino]-2,5,24,38,39-pentaoxo-2,3,4,5,6,7,23,24,25,26,36,37,38,38<i>a</i>-tetradecahidro-8,11:18,21-dieteno-23,36-(iminometano)-22<i>H</i>-13,16:31,35-dimeteno-1<i>H</i>,13<i>H</i>-[1,6,9]oxadiazaciclohexadecino[4,5-<i>m</i>][10,2,16]benzoxadiazaciclótetracoseno-26-carboxílico orienticina D (constituyente secundario): ácido (3<i>S</i>,6<i>R</i>,7<i>R</i>,22<i>R</i>,23<i>S</i>,26<i>S</i>,36<i>R</i>,38<i>aR</i>)-22-[(3-amino-3-<i>C</i>-metil-2,3,6-tridesoxi-α-<i>L</i>-<i>arabino</i>-hexopiranosil)oxi]-44-[[2-<i>O</i>-(3-amino-3-<i>C</i>-metil-2,3,6-tridesoxi-α-<i>L</i>-<i>arabino</i>-hexopiranosil)-β-<i>D</i>-glucopiranosil]oxi]-3-(carbamoilmetil)-19-cloro-7,28,30,32-tetrahidroxi-6-[[<i>R</i>]-2-(dimetilamino)-4-metilpentanoil]amino]-2,5,24,38,39-pentaoxo-2,3,4,5,6,7,23,24,25,26,36,37,38,38<i>a</i>-tetradecahidro-8,11:18,21-dieteno-23,36-(iminometano)-22<i>H</i>-13,16:31,35-dimeteno-1<i>H</i>,13<i>H</i>-[1,6,9]oxadiazaciclohexadecino[4,5-<i>m</i>][10,2,16]benzoxadiazaciclótetracoseno-26-carboxílico <i>antibacteriano (vet.)</i></p>

A: C₇₃H₈₉ClN₁₀O₂₆ 111073-20-2D: C₇₄H₉₁ClN₁₀O₂₆ 112848-46-1

159445-63-3

**pegorgoteinum**

pegorgotein

superoxide dismutase, reaction product with succinic anhydride, esters with polyethylene glycol monomethyl ether
enzyme


pégorgotéine

esters du produit de réaction de l'anhydride succinique sur la superoxyde dismutase et de monoéther méthylique de polyéthylèneglycol
enzyme

pegorgotein

esteres del producto de reaccion del anhidrido succínico con la superoxido dismutasa y del monoeter metílico del polietilenglicol
enzima

155773-57-2



m = 118 to 137 ; n = 9 to 13 ; Enz = superoxide dismutase

m = 118 à 137 ; n = 9 à 13 ; Enz = superoxyde dismutase

m = 118 a 137 ; n = 9 a 13 ; Enz = superóxido dismutasa

premafloxacinum

premafloxacin

1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(3*R*)-3-[(1*S*)-1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid
antibacterial (vet.)

prémafloxacine


acide 1-cyclopropyl-6-fluoro-8-méthoxy-7-[(3*R*)-3-[(1*S*)-1-(méthylamino)éthyl]pyrrolidin-1-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique
antibactérien (vét.)

premafloxacino

ácido 1-ciclopropil-6-fluoro-1,4-dihidro-8-metoxi-7-[(3*R*)-3-[(1*S*)-1-(metilamino)etil]-1-pirrolidinil]-4-oxo-3-quinolincarboxílico
antibacteriano (vet.)

C₂₁H₂₆FN₃O₄

143383-65-7

**priliximabum**

priliximab

immunoglobulin G 1 (human-mouse monoclonal cm-T412 anti-human antigen CD 4), disulfide with human-mouse monoclonal cm-T412 κ-chain, dimer
immunomodulator

priliximab

immunoglobuline G1 (anticorps monoclonal homme-souris cm-T412 anti-antigène CD 4 humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal homme-souris cm-T412
immunomodulateur

priliximab

inmunoglobulina G 1 (anticuerpo monoclonal hombre-ratón cm-T412 anti-antígeno CD 4 humano), dímero del disulfuro con la cadena κ del anticuerpo monoclonal hombre-ratón cm-T412
inmunomodulador

147191-91-1

prulifloxacinum

prulifloxacin

(±)-7-[4-[(*Z*)-2,3-dihydroxy-2-butenyl]-1-piperazinyl]-6-fluoro-1-methyl-4-oxo-1*H*,4*H*-[1,3]thiazeto[3,2-*a*]quinoline-3-carboxylic acid, cyclic carbonate
antibacterial

prulifloxacine


acide (±)-(1*RS*)-6-fluoro-1-méthyl-7-[4-[(5-méthyl-2-oxo-1,3-dioxol-4-yl)=méthyl]pipérazin-1-yl]-4-oxo-4*H*-[1,3]thiazéto[3,2-*a*]quinoléine-3-carboxylique
antibactérien

prulifloxacino

ácido (±)-7-[4-[(*Z*)-2,3-dihidroxi-2-butenil]-1-piperazinil]-6-fluoro-1-metil-4-oxo-1*H*,4*H*-[1,3]tiazeto[3,2-*a*]quinolina-3-carboxílico, carbonato cíclico
antibacteriano

C₂₁H₂₀FN₃O₆S

123447-62-1

and enantiomer
et énantiomère
y enantiómero**quiflaponum**
quiflapon3-(*tert*-butylthio)-1-(*p*-chlorobenzyl)- α,α -dimethyl-5-(2-quinolylmethoxy)=
indole-2-propionic acid
5-lipoxygenase-activating protein (FLAP) inhibitor


quiflapon

acide 3-[1-(4-chlorobenzyl)-3-[(1,1-diméthyléthyl)thio]-5-[(quinoléin-2-yl)=
méthoxy]-1*H*-indol-2-yl]-2,2-diméthylpropanoïque
inhibiteur de la protéine activant la 5-lipoxygénase (FLAP)

quiflapon

àcido 3-(*terc*-butiltio)-1-(*p*-clorobencil)- α,α -dimetil-5-(2-quinolilmetoxi)=
indol-2-propiónico
*inhibidor de la proteina que activa la 5-lipoxygenasa (FLAP)*C₃₄H₃₅ClN₂O₃S

136668-42-3

**rofleponidum**
rofleponide6 α ,9-difluoro-11 β ,16 α ,17,21-tetrahydroxypregn-4-ene-3,20-dione, cyclic
(*R*)-16,17-acetal with butyraldehyde
glucocorticosteroid

rofleponide


16 α ,17-[(1*R*)-butylidenedioxy]-6 α ,9-difluoro-11 β ,21-dihydroxypreg-4-ène-
3,20-dione
glucocorticostéroïde

rofleponida

6 α ,9-difluoro-11 β ,16 α ,17,21-tetrahydroxipregn-4-eno-3,20-diona,(*R*)-16,17-
acetal cíclico con butiraldehído
glucocorticosteroide

C₂₅H₃₄F₂O₆

144459-70-1

**samixogrelum**

samixogrel

(*E*)-6-[*p*-[2-(*p*-chlorobenzenesulfonamido)ethyl]phenyl]-6-(3-pyridyl)-5-hexenoic acid
platelet aggregation inhibitor

samixogrel


acide (*5E*)-6-[4-[2-[[4-chlorophényl)sulfonyl]amino]éthyl]phényl]-6-(pyridin-3-yl)hex-5-énoïque
antiagrégant plaquettaire

samixogrel

ácido(*E*)-6-[*p*-[2-(*p*-clorobencensulfonamido)etil]fenil]-6-(3-piridil)-5-hexenoico
inhibidor de la agregación plaquetaria

C₂₅H₂₅ClN₂O₄S

133276-80-9

**sanfetrinemum**

sanfetrinem

(1*S*,5*S*,8*aS*,8*bR*)-1,2,5,6,7,8,8*a*,8*b*-octahydro-1-[(*R*)-1-hydroxyethyl]-5-methoxy-2-oxoazeto[2,1-*a*]isoindole-4-carboxylic acid
antibiotic

sanfétrinem


acide (1*S*,5*S*,8*aS*,8*bR*)-1-[(1*R*)-1-hydroxyéthyl]-5-méthoxy-2-oxo-1,2,5,6,7,8,8*a*,8*b*-octahydroazéto[2,1-*a*]iso-indole-4-carboxylique
antibiotique

sanfetrinem

ácido(1*S*,5*S*,8*aS*,8*bR*)-1,2,5,6,7,8,8*a*,8*b*-octahidro-1-[(*R*)-1-hidroxietyl]-5-metoxi-2-oxoazeto[2,1-*a*]isoindol-4-carboxílico
antibiótico

C₁₄H₁₉NO₅

156769-21-0

**saprisartanum**

sapisartan

1-[[3-bromo-2-[o-(1,1,1-trifluoromethanesulfonamido)phenyl]-5-benzofuranyl]methyl]-4-cyclopropyl-2-ethylimidazole-5-carboxamide
angiotensin II receptor antagonist

sapisartan


1-[[3-bromo-2-[2-[[trifluorométhyl]sulfonyl]amino]phényl]benzofuran-5-yl]méthyl]-4-cyclopropyl-2-éthyl-1*H*-imidazole-5-carboxamide
antagoniste du récepteur de l'angiotensine II

sapisartan

1-[[3-bromo-2-[o-(1,1,1-trifluorometansulfonamido)fenil]-5-benzofuranil]metil]-4-ciclopropil-2-etilimidazol-5-carboxamida
antagonista del receptor de angiotensina II

C₂₅H₂₂BrF₃N₄O₄S

146623-69-0

**seprilosum**

seprilose

3-*O*-heptyl-1,2-*O*-isopropylidene- α -D-glucofuranose
antirheumatic

séprilose


3-*O*-heptyl-1,2-*O*-(1-méthyléthylidène)- α -D-glucofuranose
antirhumatismal

seprilosa

3-*O*-heptil-1,2-*O*-isopropiliden- α -D-glucofuranosa
antirreumático

C₁₆H₃₀O₆

133692-55-4



setipafantum

setipafant

6-(*o*-chlorophenyl)-7,10-dihydro-1-methyl-4*H*-pyrido[4',3':4,5]thieno[3,2-*f*]-s-triazolo[4,3-*a*][1,4]diazepine-9(8*H*)-carbox-*p*-anisidide
platelet-activating factor antagonist

sétipafant


6-(2-chlorophényl)-*N*-(4-méthoxyphényl)-1-méthyl-7,10-dihydro-4*H*-pyrido=[4',3':4,5]thiéno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazépine-9(8*H*)-carboxamide
antagoniste du facteur activant les plaquettes

setipafant

6-(*o*-clorofenil)-7,10-dihidro-1-metil-4*H*-pirido[4',3':4,5]tieno[3,2-*f*]-s-triazolo[4,3-*a*][1,4]diazepina-9(8*H*)-carboxi-*p*-anisida
antagonista del factor activador de las plaquetas

C₂₆H₂₃ClN₆O₂S

132418-35-0

**tagorizinum**

tagorizine

(*E*)-*N*-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-6-methyl-3-pyridine=acrylamide
antiallergic

tagorizine


(2*E*)-*N*-[4-[4-(diphénylméthyl)pipérazin-1-yl]butyl]-3-(6-méthylpyridin-3-yl)prop-2-énamide
antiallergique

tagorizina

(*E*)-*N*-[4-[4-(difenilmetil)-1-piperazinil]butil]-6-metil-3-piridinacrilamida
antialérgico

C₃₀H₃₆N₄O

118420-47-6

**talsaclidinum**

talsaclidine

(3*R*)-3-(2-propynyloxy)quinuclidine
muscarin M₁ receptor agonist


talsaclidine

(3*R*)-3-(prop-2-ynyloxy)-1-azabicyclo[2.2.2]octane
agoniste des récepteurs muscariniques M₁

talsaclidina

(3R)-3-(2-propiniloxy)quinuclidina
*agonista de los receptores muscarinicos M₁*C₁₀H₁₅NO

147025-53-4

**tasosartanum**

tasosartan

5,8-dihydro-2,4-dimethyl-8-[*p*-(*o*-1*H*-tetrazol-5-yl)phenyl]benzyl]pyrido=
[2,3-*d*]pyrimidin-7(6*H*)-one
angiotensin II receptor antagonist


tasosartan

2,4-diméthyl-8-[4-[2-(1*H*-tétrazol-5-yl)phényl]benzyl]-5,8-dihydro=
pyrido[2,3-*d*]pyrimidin-7(6*H*)-one
antagoniste du récepteur de l'angiotensine II

tasosartan

5,8-dihidro-2,4-dimetil-8-[*p*-(*o*-1*H*-tetrazol-5-ilfenil)encil]pirido=
[2,3-*d*]pirimidin-7(6*H*)-ona
*antagonista del receptor de angiotensina II*C₂₃H₂₁N₇O

145733-36-4

**tazarotenum**

tazarotene

ethyl 6-[(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate
keratolytic


tazarotène

6-[2-(4,4-diméthyl-3,4-dihydro-2*H*-1-benzothiïn-6-yl)éthynyl]pyridine-3-
carboxylate d'éthyle
kérotolytique

tazaroteno

6-[(4,4-dimetiltiocroman-6-il)etinil]nicotinato de etilo
*queratolítico*C₂₁H₂₁NO₂S

118292-40-3



toborinonum

toborinone

(±)-6-[2-hydroxy-3-(veratrylamino)propoxy]carbostyryl
cardiac stimulant

toborinone


(±)-6-[[[(2*RS*)-3-[(3,4-diméthoxybenzyl)amino]-2-hydroxypropyl]oxy]quinoléin-2(1*H*)-one
cardiotonique

toborinona

(±)-6-[2-hidroxi-3-(veratrilamino)propoxi]carbostiril
cardiotónico

C₂₁H₂₄N₂O₅

143343-83-3



and enantiomer
et énantiomère
y enantiómero

vedaprofenum

vedaprofen

(±)-4-cyclohexyl-α-methyl-1-naphthaleneacetic acid
non-steroidal anti-inflammatory

védaprophène


acide (*RS*)-2-(4-cyclohexyl-naphtalén-1-yl)propanoïque
anti-inflammatoire non-stéroïdien

vedaprofeno

ácido (±)-4-ciclohexil-α-metil-1-naftalenacético
antiinflamatorio no esteroideo

C₁₉H₂₂O₂

71109-09-6



and enantiomer
et énantiomère
y enantiómero

zaleplonum

zaleplon

3'-(3-cyanopyrazolo[1,5-*a*]pyrimidin-7-yl)-*N*-ethylacetanilide
sedative, hypnotic

zaléplone


N-[3-(3-cyanopyrazolo[1,5-*a*]pyrimidin-7-yl)phényl]-*N*-éthylacétamide
sédatif, hypnotique

zaleplon

3'-(3-cianopirazolo[1,5-*a*]pirimidin-7-il)-*N*-etilacetanilida
sedante, hipnótico

C₁₇H₁₅N₅O

151319-34-5

**zanamivirum**

zanamivir

5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galactono-2-enonic acid
antiviral

zanamivir


acide (4*S*,5*R*,6*R*)-5-(acétylamino)-4-guanidino-6-[(1*R*,2*R*)-1,2,3-trihydroxypropyl]-5,6-dihydro-4*H*-pyrane-2-carboxylique
antiviral

zanamivir

ácido 5-acetamido-2,6-anhidro-3,4,5-tridesoxi-4-guanidino-D-glicero-D-galacto-non-2-enónico
antiviral

C₁₂H₂₀N₄O₇

139110-80-8

**ziprasidonum**

ziprasidone

5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-2-indolinone
antipsychotic

ziprasidone


5-[2-[4-(1,2-benzisothiazol-3-yl)pipérazin-1-yl]éthyl]-6-chloro-1,3-dihydro-2*H*-indol-2-one
psychotrope

ziprasidona

5-[2-[4-(1,2-bencisotiazol-3-il)-1-piperazinil]etil]-6-cloro-2-indolinona
antipsicótico

C₂₁H₂₁ClN₄OS

146939-27-7



AMENDMENTS TO PREVIOUS LISTS

Proposed International Nonproprietary Names (Prop. INN): List 64 (WHO Drug Information, Vol. 4, No. 4, 1990)

- | | | |
|-------|-------------------------|---|
| p. 14 | liarozolum
liarozole | <i>replace the CAS registry number by the following:</i>
145858-51-1 |
|-------|-------------------------|---|

Proposed International Nonproprietary Names (Prop. INN): List 69 (WHO Drug Information, Vol. 7, No. 2, 1993)

- | | | |
|------|---|---|
| p. 4 | <i>delete</i>
fropenemum
fropenem | <i>insert</i>
faropenemum
faropenem |
|------|---|---|

Proposed International Nonproprietary Names (Prop. INN): List 71 Dénominations communes internationales proposées (DCI Prop.): Liste 71 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 71 (WHO Drug Information, Vol. 8, No. 2, 1994)

- | | | |
|------|---|---|
| p. 6 | candesartanum
candesartan
candésartan
candesartan | <i>replace the molecular formula and CAS registry number by the following:</i>
<i>remplacer la formule brute et le numéro dans le registre de CAS par:</i>
<i>reemplácese la fórmula empírica y el número de registro del CAS por:</i>
C ₂₄ H ₂₀ N ₆ O ₃ 139481-59-7 |
| p.16 | monteplasum
monteplase
montéplase
monteplasa | <i>add the CAS registry number by the following:</i>
<i>insérer le numéro dans le registre du CAS suivant:</i>
<i>insértese el número del registro del CAS por el siguiente:</i>
156616-23-8 |

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue de choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* ont été publiés avec la liste 71 des DCI proposées et seront, à nouveau, publiés avec la prochaine liste.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.

